Harnessing deep neurobiological insights to develop novel medicines. Built on 15 years of our field-leading neurobiology research, our clinical-stage drug candidates are designed to target …

Today, Alto harnesses 15 years of our field-leading neuroscience research and clinical data to match the right patient with the right treatment so that they can get better faster.

Oct 22, 2024 · MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of …

Nov 4, 2024 · Alto Neuroscience is on a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Contact us at …

ALTO-101 is a brain-penetrant PDE4 inhibitor designed as a novel transdermal formulation being developed for patients with schizophrenia with cognitive impairment. PDE4 is an enzyme that …

Dec 2, 2024 · ALTO-300 biomarker in defining patients with reduced medial prefrontal neural connectivity across multiple independent datasets. •In mice, we showed that 5-HT2C agonism …

3 days ago · At Alto Neuroscience, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are …

Aug 13, 2024 · MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the second quarter ended June 30, 2024, …

Christopher Nixon Cox has served as a member of our board of directors since April 2022. Since December 2021, Mr. Cox has served as Chief Executive Officer of Lightswitch Capital, a …

Jul 16, 2024 · MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of …